Stage 1 Financial Revenue and Competitors

Location

N/A

Total Funding

Finance

Industry

Estimated Revenue & Valuation

  • Stage 1 Financial's estimated annual revenue is currently $17.2M per year.(i)
  • Stage 1 Financial's estimated revenue per employee is $210,000

Employee Data

  • Stage 1 Financial has 82 Employees.(i)
  • Stage 1 Financial grew their employee count by -10% last year.

Stage 1 Financial's People

NameTitleEmail/Phone
1
Head Indirect TaxReveal Email/Phone
2
Head OnboardingReveal Email/Phone
3
Director FP&AReveal Email/Phone
4
Director SalesReveal Email/Phone
5
Marketing ManagerReveal Email/Phone
6
Sales Tax AnalystReveal Email/Phone
7
Accounting ManagerReveal Email/Phone
8
Accounting ManagerReveal Email/Phone
9
Senior State & Local Tax AccountantReveal Email/Phone
10
Senior Account ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.9M410%N/AN/A
#2
$37.7M163-10%N/AN/A
#3
$36.5M158-3%N/AN/A
#4
$6.9M4111%$101MN/A
#5
$33.3M1445%N/AN/A
#6
$43.2M1878%N/AN/A
#7
$359.3M122237%N/AN/A
#8
$3.5M249%N/AN/A
#9
$6.4M383%N/AN/A
#10
$20M95N/AN/AN/A
Add Company

What Is Stage 1 Financial?

Young, fast growing companies face many challenges, one being how to manage the financial and strategic needs for a CFO and accounting department. Stage 1 Financial meets this challenge by delivering a fully outsourced finance and accounting solution which aligns with our clients organizational and strategic priorities.

keywords:N/A

N/A

Total Funding

82

Number of Employees

$17.2M

Revenue (est)

-10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Stage 1 Financial News

2022-04-20 - ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar

as well as its 2022 financial calendar ... The Company is also pursuing a Phase 1 investigator-sponsored clinical trial in first-line...

2022-04-19 - Alnylam Pharmaceuticals Reports First Quarter 2022 Financial ...

Report topline results from Part B of the Phase 1 study of ALN-HSD in patients with NASH. Financial Results for the Quarter Ended March 31, 2022.

2022-04-19 - Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

We expect to report the initial results from a Phase 1 trial of this compound later in the year. During the quarter, we also continued...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.2M821%N/A
#2
$17.2M8222%N/A
#3
$20.6M828%N/A
#4
$24.1M836%N/A
#5
$20.8M8324%N/A